ACC 2024: Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds
ACC 2024: Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds New data indicates obicetrapib monotherapy could provide a synergistic benefit on lipid particles when used in combination with ezetimibe in people already on high-intensity statin therapy. The presentation, which was delivered at the American College of Cardiology 2024 (ACC.24) Annual Scientific Session, comes just 2 days […]
News Coverage from ACC 2024: Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM
News Coverage from ACC 2024: Ninerafaxstat Shows Promise in Phase 2 IMPROVE-HCM Trial for Nonobstructive HCM Data from the phase 2 IMPROVE-HCM trial suggest ninerafaxstat, a novel cardiac mitotrope, was well-tolerated and improved symptom burden among patients with nonobstructive hypertrophic cardiomyopathy (HCM). The data, which were presented at the American College of Cardiology 2024 (ACC.24) Annual […]
Newscasting from ACC 2024: SHASTA-2 and Plozasiran in Severe Hypertriglyceridemia, with Christie Ballantyne, MD
Newscasting from ACC 2024: SHASTA-2 and Plozasiran in Severe Hypertriglyceridemia, with Christie Ballantyne, MD New data from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions offers the cardiology community the latest insights into the effects of plozasiran in patients with severe hypertriglyceridemia. Results of the phase 2b SHASTA-2 trial, which assessed use of the investigational APOC3-targeted small […]
Newly reported from ACC 2024: Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF
Newly reported from ACC 2024: Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF A modified on-treatment analysis of the TRANSFORM-HF trial presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions showed no meaningful changes in study outcomes between torsemide and furosemide treatment in heart failure hospitalizations after discharge. “Even with that, we still saw the […]
Directly from ACC 2024: SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH
Directly from ACC 2024: SGLT2 Inhibition Across a Range of Left Ventricular Hypertrophy, with Muthiah Vaduganathan, MD, MPH An analysis of the DELIVER trial from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions is providing clinicians with new insight into the effects of SGLT2 inhibition across the range of left ventricular hypertrophy among patients with […]
Reporting from ACC 2024 – REDUCE-AMI: No Benefit to Beta Blockers Post-Myocardial Infarction If LVEF is Normal
Reporting from ACC 2024 – REDUCE-AMI: No Benefit to Beta Blockers Post-Myocardial Infarction If LVEF is Normal Use of beta-blockers following myocardial infarction does not provide significant benefit for patients with a normal left ventricular ejection fraction (LVEF), according to results of the REDUCE-AMI trial. A parallel-group, open-label trial assessing the effect of long-term beta-blocker use, results […]
News Coverage from ACC 2024 – Alberto Foà, MD, PhD: Understanding Hypotension, Benefit, and LVEF in PARAGON-HF
News Coverage from ACC 2024 – Alberto Foà, MD, PhD: Understanding Hypotension, Benefit, and LVEF in PARAGON-HF Results from PARAGON-HF suggest a higher left ventricular ejection fraction (LVEF) was associated with an increased risk of hypotension and attenuated clinical benefit among patients with heart failure treated with sacubitril/valsartan (Entresto). The data were presented by Alberto Foà, MD, […]
Don’t Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD
Don’t Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD Heading into the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, few planned data releases garnered as much attention and anticipation as the EMPACT-MI trial offered the prospect of further insight into the effects of SGLT2 inhibitors among a patient population with acute myocardial infarction. […]
Broadcasted from ACC 2024: Plozasiran Reduces Triglycerides, ApoC3 in Phase 2b SHASTA-2 Trial
Broadcasted from ACC 2024: Plozasiran Reduces Triglycerides, ApoC3 in Phase 2b SHASTA-2 Trial Use of plozasiran, an APOC3 inhibiting therapy from Arrowhead Pharmaceuticals, was associated with least squares mean reductions in triglyceride levels by 74% at 24 weeks, according to the SHASTA-2 trial. Presented as a late-breaker at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, […]
Directly from ACC 2024: Understanding Total Costs Associated with Hospitalization for Heart Failure, with Veraprapas Kittipibul, MD
Directly from ACC 2024: Understanding Total Costs Associated with Hospitalization for Heart Failure, with Veraprapas Kittipibul, MD Hospitalization costs are higher for patients with heart failure (HF) with ejection fractions of ≤40% or >40%, but the contributing factors to these costs vary significantly across the ejection fraction spectrum. The data, presented at the American College of […]
